WINNIPEG, MANITOBA--(Marketwire - August 11, 2008) - DiaMedica Inc. (TSX VENTURE: DMA), a drug discovery and clinical development company focused on a novel approach to treating type 2 diabetes, today announces enrollment of the first patient in the phase II proof of concept clinical trial with DM-99, the Company’s third drug candidate to enter phase II human trials.
